Our pipeline includes drugs for chronic and acute pain, along with a safer version of aspirin.

Our lead drug, ATB-346, targets chronic pain and inflammation arising from a wide range of medical conditions. ATB-352 addresses the urgent need for a safer, non-addictive analgesic for treating post-operative pain, where many opioid addictions begin. ATB-340 is a gastrointestinal-safe derivative of aspirin.

Development Pipeline

Click on drug candidates below to learn more.

INVESTOR INFORMATION

Keep up-to-date—check out the Investor Dashboard for share information, our Investor Presentation, financial statements, regulatory filings, latest news and more—everything you need in one place.

OUR SCIENCE

Understand the science behind our drug platform. Learn how Antibe’s drugs surpass current solutions. Investigate a diagram  detailing hydrogen sulfide’s multiple roles in human biology. 

Attention

This is an external link. Click “OK” to continue.

CANCEL OK